Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
|Eligible Ages||2 Years and Over|
Inclusion Criteria:1. Patient must have participated in core study CAIN457F2304, and must have completed the entire treatment period up to and including Week 104. 2. Patients must be deemed by the investigator to benefit from continued secukinumab therapy.
Exclusion Criteria:1. Plans for administration of live vaccines during the extension study period. 2. Any patient taking other concomitant biologic immunomodulating agent(s) except secukinumab. 3. Any patient who is deemed not to be benefiting from the study treatment based upon lack of improvement or worsening of their symptoms. All other protocol related inclusion/exclusion criteria will apply.
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
The person who is responsible for the scientific and technical direction of the entire clinical study.
|Principal Investigator Affiliation||N/A|
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
|Countries||Belgium, Germany, Italy, Poland, Russian Federation, South Africa, Spain, Turkey, United States|
The disease, disorder, syndrome, illness, or injury that is being studied.
|Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis|
NOTE: Detailed Description : data not entered
Experimental: Group 1 - Secukinumab 75 mg
Group 1 - Secukinumab (AIN457) 75 mg/0.5mL
Experimental: Group 2 - Secukinumab 150 mg
Group 2 - Secukinumab (AIN457) 150 mg/1.0mL
Drug: - AIN457
Secukinumab (AIN457) is a high-affinity fully human monoclonal anti- human antibody that target IL-17A and neutralizes activity.
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.